http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112574300-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2020-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112574300-B |
| titleOfInvention | anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof |
| abstract | The invention relates to an anti-SAR-COV-2 antibody or an antigen binding fragment thereof and application thereof, and particularly discloses that an antibody 9O21 kappa has the sequence shown in SEQ ID No: 1-3, and SEQ ID No: 4-6; antibody 9O21 λ has the amino acid sequence of SEQ ID No: 11-13, and SEQ ID No: 14-16, and light chain complementarity determining regions. The antibody of the present invention is a humanized antibody, and has low side effects and high affinity and specificity. |
| priorityDate | 2020-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 330.